China-based gene therapy has faced another reported safety concern: a boy receiving Huidagene’s gene editing therapy HG-302 for Duchenne muscular dystrophy died, according to the company’s disclosure. The report follows earlier high-profile accounts of gene-editing deaths in China, keeping scrutiny on delivery, conditioning, and trial oversight. The event adds to a growing risk-management discussion across regulatory bodies and investors, particularly around long-term follow-up and how adverse events are classified when platforms move rapidly from concept into clinical settings. In the same environment, FDA and global regulators continue to tighten how they evaluate benefit-risk evidence for advanced therapies, including requirements for confirmatory outcomes and clearer endpoints.